Výsledky vyhledávání - "E. Leibowitz"

Akademický článek

Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations

Autor: N. Lasman, M. Shalom, N. Turpashvili, G. Goldhaber, Y. Lifshitz, E. Leibowitz, G. Berger, G. Saltzman-Shenhav, A. Brom, D. Cohen, C. Avaky, G. Segal

Publikováno v: BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-6 (2020)

Abstract Background COPD exacerbations have negative impact on patients’ survival. Several risk factors for grave outcomes of such exacerbations have been descried. Muscle dysfunction and mass loss were shown to impact negatively on prognosis and s

Externí odkaz: https://doaj.org/article/45ace472ddac42aeb1252084142734ea

Zobrazit plný text záznamu

POS1015 SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE BIO-NAÏVE OR TNFi-EXPERIENCED: POOLED RESULTS FROM 4 RANDOMIZED CLINICAL TRIALS THROUGH 2 YEARS

Autor: P. Rahman, W. H. Boehncke, P. J. Mease, A. B. Gottlieb, I. Mcinnes, M. Neuhold, M. Shawi, Y. Wang, S. Sheng, P. Bergmans, A. Kollmeier, E. Theander, J. Yu, E. Leibowitz, M. Marrache, L. Coates

Publikováno v: Annals of the Rheumatic Diseases. 81:816-817

BackgroundGuselkumab (GUS), a selective IL-23p19 subunit inhibitor, demonstrated efficacy and a favorable safety profile in active psoriatic arthritis (PsA) in the Phase (Ph)21, Ph3 (DISCOVER [D]-1&2)2,3, and Ph3b COSMOS4 randomized controlled trials

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce770236f47ffce5cfdcb99e6acf235e
https://doi.org/10.1136/annrheumdis-2022-eular.219

Zobrazit plný text záznamu

AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial

Autor: D. D. Gladman, P. J. Mease, P. Bird, E. Soriano, S. D. Chakravarty, M. Shawi, S. Xu, S. Quinn, C. Gong, E. Leibowitz, L. S. Tam, P. Helliwell, A. Kavanaugh, A. Deodhar, M. Østergaard, X. Baraliakos

Publikováno v: Annals of the Rheumatic Diseases. 81:1574-1575

BackgroundEstablished criteria for classifying axial psoriatic arthritis (PsA) are lacking, and assessments of disease activity often rely on measures developed for ankylosing spondylitis (AS). There is an unmet need to systematically identify and me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6db09922819dd95b1f3b5ffe503b353f
https://doi.org/10.1136/annrheumdis-2022-eular.1551

Zobrazit plný text záznamu

Low ALT values amongst hospitalized patients are associated with increased risk of hypoglycemia and overall mortality: a retrospective, big-data analysis of 51 831 patients

Autor: E. Leibowitz, L Ahmead, Gad Segal, A Segev, Yishay Wasserstrum, Gilat Shenhav-Saltzman, Chen Avaky, M Agbaria, E Itelman, L Negro

Publikováno v: QJM : monthly journal of the Association of Physicians. 114(12)

Summary Background Sarcopenia and frailty influence clinical patients’ outcomes. Low alanine aminotransferase (ALT) serum activity is a surrogate marker for sarcopenia and frailty. In-hospital hypoglycemia is associated, also with worse clinical ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa68ed6d5c9063382bd625cfd3a64e34
https://pubmed.ncbi.nlm.nih.gov/32642782

Zobrazit plný text záznamu

Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations

Autor: G. Saltzman-Shenhav, Nir Lasman, Y. Lifshitz, Gad Segal, E. Leibowitz, G. Goldhaber, M. Shalom, A. Brom, Natia Turpashvili, D. Cohen, C. Avaky, G. Berger

Publikováno v: BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-6 (2020)

Background COPD exacerbations have negative impact on patients’ survival. Several risk factors for grave outcomes of such exacerbations have been descried. Muscle dysfunction and mass loss were shown to impact negatively on prognosis and survival.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::323ad4ada33cbdad1561de4a4ea927be
http://europepmc.org/articles/PMC7216624

Zobrazit plný text záznamu

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Autor: Petrylak, D.P. de Wit, R. Chi, K.N. Drakaki, A. Sternberg, C.N. Nishiyama, H. Castellano, D. Hussain, S.A. Fléchon, A. Bamias, A. Yu, E.Y. van der Heijden, M.S. Matsubara, N. Alekseev, B. Necchi, A. Géczi, L. Ou, Y.-C. Coskun, H.S. Su, W.-P. Bedke, J. Gakis, G. Percent, I.J. Lee, J.-L. Tucci, M. Semenov, A. Laestadius, F. Peer, A. Tortora, G. Safina, S. Garcia del Muro, X. Rodriguez-Vida, A. Cicin, I. Harputluoglu, H. Tagawa, S.T. Vaishampayan, U. Aragon-Ching, J.B. Hamid, O. Liepa, A.M. Wijayawardana, S. Russo, F. Walgren, R.A. Zimmermann, A.H. Hozak, R.R. Bell-McGuinn, K.M. Powles, T. Wong, S.-L.S. Tan, T.H. Hovey, E.J. Clay, T.D. Wan Ng, S.S. Rutten, A. Machiels, J.-P. Dumez, H. Cheng, S.Y.-S. Ferrario, C. Sengeloev, L. Jensen, N.V. Thibault, C. Laguerre, B. Joly, F. Culine, S. Becht, C. Niegisch, G. Stöckle, M. Grimm, M.-O. Schwentner, C.A. Schultze-Seemann, W. Kalofonos, H. Mavroudis, D. Papandreou, C. Karavasilis, V. Révész, J. Rosenbaum, E. Leibowitz-Amit, R. Kejzman, D. Sarid, D. Scagliotti, G.V. Bracarda, S. Massari, F. Osawa, T. Miyajima, N. Shinohara, N. Fukuta, F. Ohyama, C. Obara, W. Yamashita, S. Tomita, Y. Kawai, K. Fukasawa, S. Oyama, M. Yonese, J. Nagata, M. Uemura, M. Nishimura, K. Kawakita, M. Tsunemori, H. Hashine, K. Inokuchi, J. Yokomizo, A. Nagamori, S. Lee, H.J. Park, S.H. Rha, S.Y. Kim, Y.J. Lee, Y.-G. Vazquez Cortés, L. Lorena Urzua Flores, C. Blaisse, R.J.B. Erdkamp, F.L.G. Aarts, M.J.B. Wojcik-Tomaszewska, J. Tomczak, P. Sikora-Kupis, B. Schenker, M. Herzal, A.A. Udrea, A.A. Karlov, P. Fomkin, R. Gajate Borau, P. Grande, E. Delgado Mignorance, J.I. Su, Y.-L. Li, J.-R. Lin, C.-L. Lin, C.-C. Yeh, S.-P. Erman, M. Urun, Y. Golovko, Y. Bondarenko, I. Sinielnikov, I. Crabb, S.J. Syndikus, I. Huddart, R. Sundar, S. Chowdhury, S. Sarwar, N. Flaig, T.W. Pan, C.X. Schwarz, J.K. Cultrera, J.L. Acs, P.I. Hainsworth, J.D. Herms, B.T. Lawler, W.E. Lowe, T.E.

Background: Ramucirumab—an IgG1 vascular endothelial growth factor receptor 2 antagonist—plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the second

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::6d6c203046c19aaa2c6364316d7bcd5b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105243

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Autor: Petrylak, D.P. de Wit, R. Chi, K.N. Drakaki, A. Sternberg, C.N. Nishiyama, H. Castellano, D. Hussain, S. Fléchon, A. Bamias, A. Yu, E.Y. van der Heijden, M.S. Matsubara, N. Alekseev, B. Necchi, A. Géczi, L. Ou, Y.-C. Coskun, H.S. Su, W.-P. Hegemann, M. Percent, I.J. Lee, J.-L. Tucci, M. Semenov, A. Laestadius, F. Peer, A. Tortora, G. Safina, S. del Muro, X.G. Rodriguez-Vida, A. Cicin, I. Harputluoglu, H. Widau, R.C. Liepa, A.M. Walgren, R.A. Hamid, O. Zimmermann, A.H. Bell-McGuinn, K.M. Powles, T. Wong, S.-L.S. Tan, T.H. Hovey, E.J. Clay, T.D. Ng, S.S.W. Rutten, A. Machiels, J.-P. Dumez, H. Cheng, S.Y.-S. Ferrario, C. Sengeloev, L. Jensen, N.V. Thibault, C. Laguerre, B. Joly, F. Flechon, A. Culine, S. Becht, C. Niegisch, G. Stöckle, M. Grimm, M.-O. Gakis, G. Schultze-Seemann, W. Kalofonos, H. Mavroudis, D. Papandreou, C. Karavasilis, V. Révész, J. Geczi, L. Rosenbaum, E. Leibowitz-Amit, R. Kejzman, D. Sarid, D. Scagliotti, G.V. Bracarda, S. Massari, F. Osawa, T. Miyajima, N. Shinohara, N. Fukuta, F. Ohyama, C. Obara, W. Yamashita, S. Tomita, Y. Kawai, K. Fukasawa, S. Oyama, M. Yonese, J. Nagata, M. Uemura, M. Nishimura, K. Kawakita, M. Tsunemori, H. Hashine, K. Inokuchi, J. Yokomizo, A. Nagamori, S. Lee, H.J. Park, S.H. Rha, S.Y. Kim, Y.J. Lee, Y.-G. Cortés, L.V. Flores, C.L.U. Blaisse, R.J.B. Erdkamp, F.L.G. Aarts, M.J.B. Wojcik-Tomaszewska, J. Tomczak, P. Sikora-Kupis, B. Schenker, M. Herzal, A.A. Udrea, A.A. Karlov, P. Fomkin, R. Pulido, E.G. Mignorance, J.I.D. Gauna, D.C. Rodríguez-Vida, A. Su, Y.-L. Lin, C.-L. Lin, C.-C. Yeh, S.-P. Çiçin, I. Erman, M. Urun, Y. Golovko, Y. Bondarenko, I. Sinielnikov, I. Crabb, S. Syndikus, I. Huddart, R. Sundar, S. Chowdhury, S. Sarwar, N. Flaig, T. Pan, C.X. Schwarz, J. Cultrera, J. Hainsworth, J. Herms, B. Lawler, W. Lowe, T. Tagawa, S. Aragon-Ching, J. Vaishampayan, U.

Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab—a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::1a8b89a3304f0300e627c2edb4eb7ed0
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108124

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání